These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16877737)

  • 21. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
    Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
    Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
    Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
    Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
    Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
    J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
    Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
    J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
    Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
    Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
    Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
    Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
    J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
    Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
    Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of imexon in patients with advanced malignancy.
    Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
    J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
    Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
    Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.